Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 3 completed trials

    Completion Rate
    100%(3/3)
    Active Trials
    0(0%)
    Results Posted
    33%(1 trials)

    Phase Distribution

    Phase 1/2
    2
    50%
    Phase 2
    1
    25%
    Phase 1
    1
    25%

    Phase Distribution

    1

    Early Stage

    3

    Mid Stage

    0

    Late Stage

    Phase Distribution4 total trials
    Phase 1Safety & dosage
    1(25.0%)
    Phase 1/2Combined phases
    2(50.0%)
    Phase 2Efficacy & side effects
    1(25.0%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    100.0%

    3 of 3 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Completed(3)
    Other(1)

    Detailed Status

    Completed3
    unknown1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 1/2

    Trials by Phase

    Phase 11 (25.0%)
    Phase 1/22 (50.0%)
    Phase 21 (25.0%)

    Trials by Status

    unknown125%
    completed375%

    Recent Activity

    0 active trials
    Showing 4 of 4
    completedphase_1

    Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

    NCT03783130
    completedphase_2

    Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

    NCT00031733
    unknownphase_1_2

    Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

    NCT00007826
    completedphase_1_2

    Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma

    NCT00004184

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT03783130Phase 1

    Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

    Completed
    NCT00031733Phase 2

    Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

    Completed
    NCT00007826Phase 1/2

    Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

    Unknown
    NCT00004184Phase 1/2

    Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma

    Completed

    All 4 trials loaded

    Drug Details

    Intervention Type
    Varies by study
    Total Trials
    4